August 19, 2026

Amylyx +48.6% to $35.11 on LUCIDITY, $350M Raise, Guggenheim $55 PT, Silence $201.3M Close, AMX0318 Follow-On

Amylyx AMLX +48.6% weekly to $35.11 on LUCIDITY, $350M raise, Guggenheim $55/Mizuho $30 PT lifts. Silence closes $201.3M. AMX0318 long-acting follow-on.

4 stories · Covering industry, clinical-trials

Editor's Note

Wednesday's peptide news follows through on Monday's Amylyx Pharmaceuticals (NASDAQ: AMLX) Phase 3 LUCIDITY win with the market reprice, capital raise, and analyst-target reset that typically follow a first-in-class Phase 3 hit in a serious rare-disease indication with no currently approved therapy. AMLX shares surged approximately 48.6% over the week to $35.11 (near the 52-week high of $35.39, up roughly 349% year-over-year) on volume exceeding 23.6 million shares Monday, the stock's best day in nearly four years. Amylyx concurrently priced a $350 million underwritten public offering of common stock to fund the avexitide (exendin 9-39, a GLP-1 receptor antagonist peptide) commercial launch preparation, NDA submission activities, and broader pipeline advancement including AMX0318, the next-generation long-acting GLP-1 receptor antagonist Amylyx nominated as a development candidate in January 2026 through a research collaboration with Danish peptide discovery specialist Gubra A/S. Analyst price target lifts landed: Guggenheim raised to $55 from $40 (Buy), Mizuho raised to $30 from $24 (Outperform), and H.C. Wainwright raised to $20 from $16. Seeking Alpha upgraded coverage to Strong Buy citing LUCIDITY outcome and 2026 catalysts. Silence Therapeutics (NASDAQ: SLN) separately closed its upsized public offering with final gross proceeds of approximately $201.3 million for 14,907,407 ADSs at $13.50 per ADS after full underwriter exercise of the 30-day overallotment option, following the August 10 SANRECO Phase 2 win in polycythemia vera.

Industry

Amylyx Pharmaceuticals (NASDAQ: AMLX) Shares Surged Approximately 48.6% Over the Week to $35.11 (Near the 52-Week High of $35.39, Up Roughly 349% Year-Over-Year) on Volume Exceeding 23.6 Million Shares Monday August 18 (the Stock's Best Day in Nearly Four Years) Following the LUCIDITY Phase 3 Primary Endpoint Hit for Avexitide (55% Reduction in Composite Level 2 and Level 3 Hypoglycemic Events, P=0.000003) in Post-Bariatric Hypoglycemia; The Company Concurrently Priced a $350 Million Underwritten Public Offering of Common Stock to Fund Avexitide Commercial Launch Preparation, NDA Submission Activities, and Broader Pipeline Advancement; Analyst Price Target Lifts Landed Broadly With Guggenheim to $55 From $40 (Buy), Mizuho to $30 From $24 (Outperform), and H.C. Wainwright to $20 From $16; Seeking Alpha Upgraded Coverage to Strong Buy

Amylyx Pharmaceuticals (NASDAQ: AMLX) shares surged approximately 48.6% over the week to $35.11 (near the 52-week high of $35.39, up roughly 349% year-over-year) on volume exceeding 23.6 million shares Monday August 18, 2026, the stock's best day in nearly four years. The rally followed Monday's LUCIDITY Phase 3 primary endpoint hit for avexitide (exendin 9-39, a peptide GLP-1 receptor antagonist administered as 90 mg once-daily subcutaneous injection) documenting a 55% reduction in the composite of Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003) in post-bariatric hypoglycemia. Amylyx concurrently priced a $350 million underwritten public offering of common stock. Use of proceeds: avexitide commercial launch preparation (Q4 2026 NDA submission, potential 2027 launch if approved), NDA submission activities, broader pipeline advancement including AMX0318 IND-enabling studies, and general corporate purposes. The offering adds immediate dilution risk to the extended rally but positions Amylyx for the multi-quarter launch execution ahead. Analyst price target lifts: Guggenheim raised to $55 from $40 while maintaining Buy; Mizuho analyst Graig Suvannavejh raised to $30 from $24 while maintaining Outperform; H.C. Wainwright raised to $20 from $16. Seeking Alpha upgraded coverage to Strong Buy citing LUCIDITY outcome, avexitide commercial trajectory, and additional 2026 catalysts. The re-rating pattern is typical for first-in-class Phase 3 wins in serious rare-disease indications with no currently approved competitor.

#amylyx-pharmaceuticals #amlx #48-6-percent-surge #35-11-stock-price #350-million-offering #lucidity-aftermath #guggenheim-55-pt #mizuho-30-pt #hc-wainwright-20-pt #strong-buy-upgrade #avexitide-commercial-preparation

Industry

Silence Therapeutics (NASDAQ: SLN) Announced the Closing of Its Upsized $201.3 Million Underwritten Public Offering of American Depositary Shares Priced August 11 at $13.50 per ADS for 12,962,963 ADSs, With Underwriters (Jefferies, Morgan Stanley, Cantor Fitzgerald, and William Blair as Joint Book-Running Managers) Fully Exercising Their 30-Day Option to Purchase an Additional 1,944,444 ADSs Bringing Total to 14,907,407 ADSs; The Financing Follows the August 10 Phase 2 SANRECO Trial Win in Polycythemia Vera With Divesiran (First-in-Class TMPRSS6-Targeting siRNA) Achieving an 88% Response Rate Versus 19% on Placebo (P<0.0001, 69% Placebo-Adjusted Response Rate); Capital Advances Divesiran Into Phase 3 (Planned H1 2027) Plus Broader Hepatic-Target GalNAc-Conjugated siRNA Portfolio Progression

Silence Therapeutics (NASDAQ: SLN) announced the closing of its upsized $201.3 million underwritten public offering of American Depositary Shares. Terms: priced August 11 at $13.50 per ADS for 12,962,963 ADSs. The underwriters (Jefferies, Morgan Stanley, Cantor Fitzgerald, and William Blair as joint book-running managers) fully exercised their 30-day option to purchase an additional 1,944,444 ADSs, bringing the total offering to 14,907,407 ADSs and gross proceeds to approximately $201.3 million. The financing follows the August 10 Phase 2 SANRECO trial win in polycythemia vera with divesiran (first-in-class TMPRSS6-targeting siRNA that increases hepcidin production to restrict iron availability to bone marrow) achieving an 88% response rate versus 19% on placebo (P<0.0001, 69% placebo-adjusted response rate) in 48 phlebotomy-dependent patients over 36 weeks. Use of proceeds: advance divesiran into Phase 3 (planned initiation H1 2027 evaluating Q12W dosing versus placebo) plus broader pipeline progression including hepatic-target GalNAc-conjugated siRNA portfolio across TMPRSS6, complement component 3 (SLN-124/SLN-501), and other liver-targeted RNAi candidates. Divesiran has FDA Fast Track and Orphan Drug designations for polycythemia vera.

#silence-therapeutics #sln #201-3-million-offering #public-offering-close #divesiran #sanreco #polycythemia-vera #sirna #tmprss6 #phase-3-h1-2027 #jefferies #morgan-stanley #galnac-conjugation

Clinical Trials

The Amylyx Pipeline Follow-On AMX0318, a Novel Long-Acting GLP-1 Receptor Antagonist Development Candidate Identified in Collaboration With Danish Peptide Discovery Specialist Gubra A/S (Nominated January 2026), Is Progressing Through Investigational New Drug (IND)-Enabling Studies With an IND Filing Targeted for 2027; AMX0318 Demonstrated Robust Preclinical and Chemical Properties Including a Favorable Pharmacokinetic Profile That May Support Long-Acting Administration (Extending Beyond Avexitide's Once-Daily Subcutaneous Injection Format), Strong Chemical Stability, High In Vitro Potency, In Vivo Activity and Tolerability, and High Solubility; The Follow-On Candidate Extends Amylyx's Franchise Beyond Avexitide Into a Longer-Duration Product Format That Could Address Post-Bariatric Hypoglycemia and Additional Rare Diseases

The Amylyx pipeline follow-on AMX0318, a novel long-acting GLP-1 receptor antagonist development candidate identified in collaboration with Danish peptide discovery specialist Gubra A/S (nominated January 2026), is progressing through Investigational New Drug (IND)-enabling studies with an IND filing targeted for 2027. Development context: AMX0318 was selected as a development candidate after demonstrating a favorable pharmacokinetic profile that may support long-acting administration (extending beyond avexitide's once-daily subcutaneous injection format), strong chemical stability, high in vitro potency, evidence of in vivo activity and tolerability, and high solubility. The Gubra A/S collaboration draws on Gubra's peptide discovery platform (which has also contributed to Boehringer Ingelheim's survodutide dual GLP-1/glucagon agonist for obesity) combined with Amylyx's expertise in GLP-1 receptor antagonist biology developed through the avexitide program. The follow-on candidate extends Amylyx's franchise beyond avexitide into a longer-duration product format that could address post-bariatric hypoglycemia (potentially with weekly or longer dosing) and additional rare diseases where excessive endogenous GLP-1 signaling drives disease. The long-acting profile could substantially improve adherence and quality of life for patients compared to daily subcutaneous injection, and the IND filing in 2027 would position Amylyx to begin Phase 1 human studies as avexitide is entering commercial launch.

#amylyx-pharmaceuticals #amlx #amx0318 #long-acting-glp-1-receptor-antagonist #gubra-collaboration #danish-peptide-discovery #ind-2027 #avexitide-follow-on #post-bariatric-hypoglycemia #long-duration-peptide #franchise-extension

Industry

The Amylyx LUCIDITY Win Establishes GLP-1 Receptor Antagonism as a New Commercial Category in Peptide Therapeutics, Distinct From the Semaglutide-Tirzepatide-Retatrutide GLP-1 Agonist Class That Reduces Appetite by Activating the GLP-1 Receptor: Antagonists Block the Same Receptor Without Activating It, Producing the Mechanistic Opposite Effect and Addressing Indications Where Excessive Endogenous GLP-1 Signaling Drives Disease (Post-Bariatric Hypoglycemia After Roux-en-Y Gastric Bypass, Congenital Hyperinsulinism, and Certain Tumor-Related Hyperinsulinemic Hypoglycemia); The Category Sizing Is Smaller Than the Agonist Class (Roughly 8% of Roux-en-Y Gastric Bypass Patients Develop Long-Term PBH Versus the Broad Obesity Population Addressable by Agonists) but the Rare-Disease Framing Supports Substantially Higher Per-Patient Pricing and Faster FDA Pathway Under Breakthrough Therapy Designation

The Amylyx LUCIDITY win establishes GLP-1 receptor antagonism as a new commercial category in peptide therapeutics, distinct from the semaglutide-tirzepatide-retatrutide GLP-1 agonist class. Mechanistic contrast: agonists (semaglutide, tirzepatide, retatrutide, orforglipron, ribupatide) bind and activate the GLP-1 receptor to reduce appetite and slow gastric emptying, producing the substantial weight loss that anchors the obesity drug class. Antagonists (avexitide, and the follow-on AMX0318) bind the same receptor without activating it, blocking excessive endogenous GLP-1 signaling that drives disease. Indication set: post-bariatric hypoglycemia (PBH, affecting roughly 8% of Roux-en-Y gastric bypass patients long-term as a serious postprandial hypoglycemia complication driven by GI anatomy reconfiguration and the resulting exaggerated GLP-1 response after meals), congenital hyperinsulinism (a rare pediatric disease of pancreatic islet-cell dysregulation), and certain tumor-related hyperinsulinemic hypoglycemia (rare islet-cell tumors). Commercial framing: the category is smaller than the agonist class by patient count but the rare-disease indications support substantially higher per-patient pricing (typical rare-disease pricing at $200,000 to $500,000 per patient per year versus obesity-drug list prices around $12,000 to $15,000 per year), faster FDA pathway under Breakthrough Therapy Designation (which avexitide holds), and less competition. The Amylyx franchise anchors this category with avexitide going to NDA by end 2026 plus AMX0318 IND filing planned 2027 to extend into longer-acting formats.

#glp-1-receptor-antagonist #new-commercial-category #peptide-therapeutics #avexitide #amx0318 #amylyx-pharmaceuticals #post-bariatric-hypoglycemia #congenital-hyperinsulinism #rare-disease-pricing #breakthrough-therapy-designation #mechanistic-opposite